The Asia-Pacific healthcare CDMO market is projected to grow at a significant CAGR during the forecast period (2020-2026). The significant growth in the pharmaceutical contract manufacturing industry in China, India, and Japan further provides ample opportunity to the market. The pharmaceutical contract manufacturing firms are also focusing on expanding their business operations.
Browse the full report description Asia-Pacific Healthcare Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) and Forecast 2020-2026 at https://www.omrglobal.com/industry-reports/asia-pacific-healthcare-cdmo-market
For example, in 2017, Fujifilm Holdings plans to widen its biopharmaceutical contract manufacturing business. The company is expanding the capacity of its culture tanks by the year 2019 and plans to hire more engineers for proper management of its manufacturing operations. This enables the company to offer much efficient manufacturing services to the pharmaceutical industry.
Moreover, the Asia-Pacific regenerative medicine industry is also expected to grow in near future due to ease in regulations, supporting to drive the biotech industry in Asia-Pacific. For example, in 2014, the Japanese government passed the PMD (Pharmaceutical and Medical Device Act). Under the act, a product related to new cell therapy can be tentatively approved by the regulatory authorities as its safety and effectiveness have been established. This act supports regenerative medicine companies to shorten the time lag between the product development and market introduction of new products.
The effect of the PMD act has been shown in the Life Science World 2016 that attracted a large number of companies specializing in experiment equipment, cell culture materials companies. Moreover, it also attracts a large number of cell CMO firms. This exhibition signifies the positive vision of the regenerative medicine industry in the region that further spurs the healthcare CDMO market in the region.
Market Coverage
|
Report Elements |
Details |
|
Study Period |
2019-2026 |
|
Base year |
2019 |
|
Forecast period |
2020-2026 |
|
Segments Covered |
By Services |
|
Regions Covered |
China, India, Japan, and the Rest of Asia-Pacific |
|
Key Companies Profiled |
AbbVie Inc., Almac Group Ltd., B. Braun Melsungen AG, Boehringer Ingelheim
International GmbH, Lonza
Group Ltd., Pfizer Inc., and
others |
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
o Recommendations
Asia-Pacific healthcare CDMO Market – Segmentation
By Services
o Clinical
o Preclinical
o Laboratory Services
o Active Pharmaceutical Ingredients( API)
o Finish Dosage Formulations
o Medical Devices
Asia-Pacific Healthcare CDMO Market – Segmentation by Region
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/asia-pacific-healthcare-cdmo-market